Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company undertakes contracts with pharmaceutical companies for the use of SphygmoCor XCEL devices; provides lab and data management services for clinical trials comprising end-to-end service that delivers clean datasets to study sponsors. It also develops home vascular health solutions, remote patient monitoring, decentralized clinical trials and solutions wearables, and medical health apps under the CONNEQT name, as well as CONNEQT Pulse device, a home-based heart health vital signs monitoring system, that measures central blood pressure, arterial waveforms, and various other proprietary arterial health parameters through its SphygmoCor technology. The company serves hospitals, clinics, research institutions and pharmaceutical companies. It has strategic collaboration agreement with LifeQ, Inc for wearable devices. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is based in Sydney, Australia.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Buy
Sell